Cargando…

Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms

PURPOSE OF REVIEW: We will discuss recent advances in the development of nanoparticle vaccines presenting HIV-1 envelope trimer vaccines and the immunological mechanisms by which they act. RECENT FINDINGS: The multivalent presentation of Env trimers on nanoparticles is a promising strategy to increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouwer, Philip J.M., Sanders, Rogier W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060048/
https://www.ncbi.nlm.nih.gov/pubmed/30994503
http://dx.doi.org/10.1097/COH.0000000000000549
_version_ 1783504156424667136
author Brouwer, Philip J.M.
Sanders, Rogier W.
author_facet Brouwer, Philip J.M.
Sanders, Rogier W.
author_sort Brouwer, Philip J.M.
collection PubMed
description PURPOSE OF REVIEW: We will discuss recent advances in the development of nanoparticle vaccines presenting HIV-1 envelope trimer vaccines and the immunological mechanisms by which they act. RECENT FINDINGS: The multivalent presentation of Env trimers on nanoparticles is a promising strategy to increase Env immunogenicity. Recent studies have shed light on how Env nanoparticles increase lymph node trafficking and germinal center formation by using the lectin-mediated complement pathway and enhancing the interaction with naïve B cells. Meanwhile, research on different nanoparticle platforms has resulted in improved designs, such as liposomes with improved stability, and the emergence of novel platforms such as protein nanoparticles that self-assemble in vitro. Immmunogenicity studies with these nanoparticles delineate the advantages and expose the limitations of the different nanoparticle platforms. SUMMARY: It is becoming increasingly clear that HIV-1 vaccine research might benefit greatly from using nanoparticles presenting Env trimers, particularly during the priming stage of immunization. Among the different nanoparticles that are being pursued, in vitro-assembling nanoparticles allow for greater control of Env quality making them a promising nanoparticle platform.
format Online
Article
Text
id pubmed-7060048
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-70600482020-03-19 Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms Brouwer, Philip J.M. Sanders, Rogier W. Curr Opin HIV AIDS BROAD NEUTRALISING AND NON-NEUTRALISING ANTIBODIES: Edited by Hugo Mouquet and Olivier Schwartz PURPOSE OF REVIEW: We will discuss recent advances in the development of nanoparticle vaccines presenting HIV-1 envelope trimer vaccines and the immunological mechanisms by which they act. RECENT FINDINGS: The multivalent presentation of Env trimers on nanoparticles is a promising strategy to increase Env immunogenicity. Recent studies have shed light on how Env nanoparticles increase lymph node trafficking and germinal center formation by using the lectin-mediated complement pathway and enhancing the interaction with naïve B cells. Meanwhile, research on different nanoparticle platforms has resulted in improved designs, such as liposomes with improved stability, and the emergence of novel platforms such as protein nanoparticles that self-assemble in vitro. Immmunogenicity studies with these nanoparticles delineate the advantages and expose the limitations of the different nanoparticle platforms. SUMMARY: It is becoming increasingly clear that HIV-1 vaccine research might benefit greatly from using nanoparticles presenting Env trimers, particularly during the priming stage of immunization. Among the different nanoparticles that are being pursued, in vitro-assembling nanoparticles allow for greater control of Env quality making them a promising nanoparticle platform. Lippincott Williams & Wilkins 2019-07 2019-02-25 /pmc/articles/PMC7060048/ /pubmed/30994503 http://dx.doi.org/10.1097/COH.0000000000000549 Text en Copyright © 2019 Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle BROAD NEUTRALISING AND NON-NEUTRALISING ANTIBODIES: Edited by Hugo Mouquet and Olivier Schwartz
Brouwer, Philip J.M.
Sanders, Rogier W.
Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
title Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
title_full Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
title_fullStr Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
title_full_unstemmed Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
title_short Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
title_sort presentation of hiv-1 envelope glycoprotein trimers on diverse nanoparticle platforms
topic BROAD NEUTRALISING AND NON-NEUTRALISING ANTIBODIES: Edited by Hugo Mouquet and Olivier Schwartz
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060048/
https://www.ncbi.nlm.nih.gov/pubmed/30994503
http://dx.doi.org/10.1097/COH.0000000000000549
work_keys_str_mv AT brouwerphilipjm presentationofhiv1envelopeglycoproteintrimersondiversenanoparticleplatforms
AT sandersrogierw presentationofhiv1envelopeglycoproteintrimersondiversenanoparticleplatforms